The net proceeds from the issue will be utilised towards the purchase of machinery, modernising existing units and expansion of its R&D facilities
Ind-Ra expects IPM revenue to grow over 12% YoY in FY22
The DGTR has recommended US $ 3.2 per kg and US $ 3.55 per kg duty on imports
The global CRAMS segment is expected to clock 6.2% CAGR over CY21-26E to touch US $ 170 billion
Hetero’s drug is a biosimilar version of Roche’s Actemra/RoActemra and will be available at the end of this month
The Covid-19 pandemic has exposed the divide that exists between rich and developing nations and to address these challenges the World Health Organisation (WHO), has compiled a list of innovative health technologies that aim to bridge the gap
The segment delivered strong sales growth of 20% YoY
Domestic business was up 41.9% YoY and 27.7% QoQ
Trillium’s portfolio includes biologics that are designed to enhance the ability of patients’ innate immune system to detect and destroy cancer cells
FDA approval of the first interchangeable biosimilar insulin will drive the US Insulin biosimilar market, says Kuick Research.
Subscribe To Our Newsletter & Stay Updated
